FindTrial
Sign In

A Study of DTC in Patients With AIDS and AIDS Related Complex

A Study of DTC in Patients With AIDS and AIDS Related Complex

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00002069
Enrollment
Unknown
Registered
2001-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Ditiocarb, Acquired Immunodeficiency Syndrome, AIDS-Related Complex

Brief summary

To determine if ditiocarb sodium (sodium diethyldithiocarbamate; DTC) restores immune and host defense function; if DTC ameliorates the AIDS related complex (ARC) symptoms in patients with AIDS and ARC; if DTC prevents progression from ARC to AIDS or progression of AIDS; and if DTC prolongs survival in AIDS.

Interventions

DRUGDitiocarb sodium

Sponsors

Merieux Institute
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Concurrent Medication: Allowed: * Zidovudine (AZT).

Exclusion criteria

Co-existing Condition: Patients with the following are excluded: * Active opportunistic infection or progressive Kaposi's sarcoma (KS). * Dementia. * Lymphoma. Concurrent Medication: Excluded within 3 weeks of study entry: * Other experimental AIDS therapy. Patients with the following are excluded: * Active opportunistic infection or progressive Kaposi's sarcoma (KS). Patients must be either HIV seropositive or have AIDS or AIDS related complex (ARC) and have life expectancy of at least 6 months.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026